At a glance
ClinicalIndex Comparison RecordPhase 2Active· 41 enrolled
Drug / intervention
Talimogene Laherparepvec (T-VEC) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Talimogene Laherparepvec (T-VEC) Administered Concurrently With the Anti-PD1 Monoclonal Antibody Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma
In Brief
A Phase 2 clinical trial evaluating Talimogene Laherparepvec (T-VEC) and Pembrolizumab for Sarcoma and 2 related conditions. Active but no longer recruiting, targeting 41 participants across 5 sites.
Detailed Summary
The purpose of this study is to determine how well the combination of therapy of talimogene laherparepvec (T-VEC) and pembrolizumab works in the treatment of patients with sarcoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSarcoma, Epithelioid Sarcoma, Cutaneous Angiosarcoma
CountriesUnited States
CollaboratorsAmgen, Merck Sharp & Dohme LLC
Timeline
Phase 2ActiveOverdue
2017201820192020202120222023202420252026
First PostedMar 2017
Enrollment StartMar 2017
Primary CompletionJul 2025
Study CompletionMar 2026
TodayJul 2026
First PostedMar 3, 2017
Enrollment StartMar 3, 2017
Primary CompletionJul 22, 2025
Study CompletionMar 1, 2026
TodayJul 2, 2026
Enrollment to primary: 8.4 yearsPosted 9.3 years ago
Interventions
Talimogene Laherparepvec (T-VEC)drug
Talimogene laherparepvec treatment will be given at Day 1 Week 1, and every 3 weeks thereafter .
Pembrolizumabdrug
Pembrolizumab will be given at Day 1 week 1 and every 3 weeks thereafter.